Company profile: Stallergenes Greer
1.1 - Company Overview
Company description
- Provider of allergy immunotherapy products and services and molecular diagnostics for respiratory allergies, spanning sublingual and oral treatments for allergic rhinitis, asthma, grass pollen, house dust mite, and peanut allergies. Products include Staloral, Oralair, Actair, Palforzia, SLIT-liquid, and tools to identify specific allergens to guide prescription and composition of immunotherapies.
Products and services
- Staloral: Sublingual immunotherapy engineered to treat allergic rhinitis and asthma, evaluated for tolerability and efficacy across short- and long-term regimens
- Actair: Sublingual immunotherapy tablet created for house dust mite allergies, studied for tolerability and efficacy over different treatment periods
- Oralair: Sublingual tablet architected for grass pollen allergies, assessed for tolerability and efficacy over various treatment durations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Stallergenes Greer
xCella Biosciences
HQ: United States
Website
- Description: Provider of antibody discovery technologies, offering a platform to screen single B cells and develop therapeutics via protein engineering. Products include the OmniAb Discovery Platform and transgenic animal systems: OmniRat, OmniMouse, OmniChicken for generating fully human antibodies; OmniFlic and OmniClic for bispecific discovery; and xPloration integrated hardware/software for high-dimensional measurement and analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full xCella Biosciences company profile →
OncoPep
HQ: United States
Website
- Description: Provider of investigational multi-peptide therapeutic cancer vaccines and adoptive T cell therapies, including PVX-410 for patients with triple negative breast cancer (TNBC) and asymptomatic multiple myeloma (MM)/smoldering multiple myeloma (SMM); MTAA-420 for multiple myeloma; and second-generation vaccines PVX-024/PVX-510 to enhance the first iteration of OncoPep's vaccine and expand to additional HLA subtypes, such as HLA-A24.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoPep company profile →
Xyphos
HQ: United States
Website
- Description: Provider of CAR-T cell therapy platforms for treating relapsed hematological malignancies and solid tumors. Offers ACCEL, which uses engineered ligands to precisely control activity and targeting of universal convertibleCAR-T with tumor-specific antibodies, and ConvertibleCAR, a technology modifying NKG2D to enable flexible multi-antigen targeting and enhanced immune cell activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xyphos company profile →
Selexis
HQ: Switzerland
Website
- Description: Provider of proprietary technology and highly specialized expertise for mammalian (suspension-adapted CHO-K1) cell line generation, helping translate scientific innovation into life-saving medicines for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexis company profile →
Simcha Therapeutics
HQ: United States
Website
- Description: Provider of engineered cytokine immunotherapies for cancer, including ST-067, an engineered IL-18 variant designed to overcome the IL-18BP decoy receptor, in Phase 1 trials for solid tumors; ST-067 plus Keytruda® in Phase 1; preclinical ST-067 combination therapies; and undisclosed cytokine therapeutic programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Simcha Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Stallergenes Greer
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Stallergenes Greer
2.2 - Growth funds investing in similar companies to Stallergenes Greer
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Stallergenes Greer
4.2 - Public trading comparable groups for Stallergenes Greer
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →